TRGT Share Price

Open 1.35 Change Price %
High 1.35 1 Day -0.68 -41.46
Low 0.82 1 Week 0.00 0.00
Close 0.96 1 Month 0.00 0.00
Volume 197793 1 Year 0.00 0.00
52 Week High 112.00
52 Week Low 52.11
TRGT Important Levels
Resistance 2 1.45
Resistance 1 1.25
Pivot 1.04
Support 1 0.67
Support 2 0.47
NASDAQ USA Most Active Stocks
ASTI 0.01 0.00%
QCOM 54.88 -12.72%
QCOM 54.88 -12.72%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
More..
NASDAQ USA Top Gainers Stocks
EDMC 0.02 100.00%
CPSL 0.10 66.67%
LOCM 0.09 50.00%
ACFN 0.30 30.43%
LTRE 2.85 29.55%
WRES 0.09 28.57%
QKLS 0.14 27.27%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Targacept, Inc. (NASDAQ: TRGT)

TRGT Technical Analysis 5
As on 20th Aug 2015 TRGT Share Price closed @ 0.96 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.54 & Strong Sell for SHORT-TERM with Stoploss of 2.60 we also expect STOCK to react on Following IMPORTANT LEVELS.
TRGT Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
TRGT Other Details
Segment EQ
Market Capital 139070800.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.targacept.com
TRGT Address
TRGT
100 North Main Street
Suite 1510
Winston-Salem, NC 27101
United States
Phone: 336-480-2100
Fax: 336-480-2107
Interactive Technical Analysis Chart Targacept, Inc. ( TRGT NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Targacept, Inc.
TRGT Business Profile
Targacept, Inc. is a biopharmaceutical company. The Company is engaged in the design, discovery and development of NNR Therapeutics for the treatment of diseases and disorders of the nervous system. The Company's NNR Therapeutics target neuronal nicotinic receptors (NNRs). As of December 31, 2011, the Company had multiple clinical-stage product candidates and preclinical programs in areas. The Company's drug discovery activities utilize computer-based molecular design methodologies and biological and chemical data for a library of diverse compounds developed and collected. The Company refers to these technologies collectively as Pentad. Its clinical-stage product candidates include TC-5214, TC-5619, TC-6987, AZD3480 (TC-1734), AZD1446 (TC-6683), TC-6499 and TC-6987.